Avalo director granted options on 20,100 shares

Avalo Therapeutics director Aaron Kantoff received a new stock option grant as part of his compensation.

Rhea-AI Filing Summary

Avalo Therapeutics director Aaron Kantoff received a new stock option grant as part of his compensation. On the grant date, he was awarded options covering 20,100 shares of Avalo Therapeutics common stock at an exercise price of $13.96 per share. These options vest 100% on the first anniversary of the grant date, as long as he continues serving as a director on that date, and expire on June 2, 2036. After this grant, his total reported stock option holdings from this award are 20,100 options, with no open-market buying or selling involved.

Insider Trade Summary

Grant/Award: 20,100 shares

Grant/Award 1 txn

Insider KANTOFF AARON

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,100 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

Key Figures

Option grant size: 20,100 options Exercise price: $13.96 per share Expiration date: June 2, 2036 +3 more

6 metrics

Option grant size 20,100 options Stock options on common stock granted to director

Exercise price $13.96 per share Strike price for newly granted stock options

Expiration date June 2, 2036 Options expire if not exercised by this date

Vesting schedule 100% after 1 year Cliff vesting on first anniversary of grant, service-based

Post-transaction holdings 20,100 options Total options reported following this grant

Transaction code A (grant/award) Form 4 code indicating compensation-related acquisition

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 13.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-02T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The stock option vests 100% on the first anniversary of the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Avalo Therapeutics (AVTX) director Aaron Kantoff report on this Form 4?

Aaron Kantoff reported receiving a stock option grant for 20,100 shares of Avalo Therapeutics common stock. The award is a compensation-related grant, not an open-market trade, providing the right to buy shares at a fixed exercise price in the future.

How many Avalo Therapeutics (AVTX) shares are covered by Aaron Kantoff’s new stock options?

The grant covers options on 20,100 shares of Avalo Therapeutics common stock. These options give him the right to purchase those shares at a predetermined price if they vest and are exercised before their expiration date in 2036.

What is the exercise price and expiration date of Aaron Kantoff’s Avalo Therapeutics (AVTX) options?

The stock options have an exercise price of $13.96 per share and expire on June 2, 2036. Kantoff can only benefit from them if the options vest and Avalo’s share price exceeds the exercise price before expiration.

When do Aaron Kantoff’s Avalo Therapeutics (AVTX) stock options vest?

The options vest 100% on the first anniversary of the grant date, assuming Kantoff continues serving as a director through that date. If he does, all 20,100 options become exercisable at once rather than vesting gradually over several years.

Did Aaron Kantoff buy or sell Avalo Therapeutics (AVTX) shares in the market in this filing?

No, this filing reports a stock option grant, not an open-market share purchase or sale. The award represents compensation in the form of options, giving future rights to buy shares, rather than an immediate cash transaction in Avalo’s stock.

How many Avalo Therapeutics (AVTX) options does Aaron Kantoff hold after this grant?

Following this transaction, Kantoff is reported as holding 20,100 stock options from this award. These options are direct holdings and relate to the newly granted compensation, with no additional derivative positions shown in this specific filing excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KANTOFF AARON

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.96	06/02/2026		A		20,100		(1)	06/02/2036	Common Stock	20,100	$0	20,100	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)